Dennis S. Charney, MD

Ketamine Infusions and Written Exposure Therapy for Chronic PTSD

April 2, 2025

Preliminary findings suggest that the combined treatment may yield large and durable symptom reductions for patients with severe chronic PTSD

Adriana Feder, Oneysha Brown, Sarah B. Rutter, et al

Letter to the Editor

Building Resilience and Well-Being in Health Care Workers in the COVID-19 Era

July 27, 2021

This reply to a commenting letter by Modesto-Lowe and colleagues discusses ongoing work being done to promote and enhance resilience among health care workers.

Lauren Peccoralo, Jonathan Depierro, Jordyn H. Feingold, et al

Brief Report

Psychological Resilience in Frontline Health Care Workers During COVID-19

December 29, 2020

Read this brief report examining stressors as well as factors associated with resilience among New York City health care workers in the acute phase of the COVID-19 pandemic.

Robert H. Pietrzak, Jordyn H. Feingold, Adriana Feder, et al

Original Research

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

September 2, 2014

James W. Murrough, Andrew M. Perez, Sanjay J. Mathew, et al

Letter to the Editor

A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression

March 15, 2011

James W. Murrough, Andrew M. Perez, Sanjay J. Mathew, et al

Original Research

Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the Cerebrospinal Fluid of Civilians With Posttraumatic Stress Disorder Before and After Treatment With Paroxetine

December 28, 2010

Alexander Neumeister, Dennis S. Charney, Peixiong Yuan, et al

Original Research

Reduced Posterior Hippocampal Volume in Posttraumatic Stress Disorder

July 31, 2008

Alexander Neumeister, Dennis S. Charney, Wayne C. Drevets, et al

Original Research

Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Double-Blind, Randomized, Controlled Trial

February 1, 2004

Robert M. Berman, Dennis S. Charney, Gerard Sanacora, et al

Article

Overview of Psychiatric Disorders and the Role of Newer Antidepressants

January 1, 2002

Kathleen T. Brady, A. John Rush, Dennis S. Charney, et al

Article

Norepinephrine Dysfunction in Depression

August 30, 2000

Dennis S. Charney, Amit Anand

Article

Models of Antidepressant Action

June 1, 1999

Robert M. Berman, Dennis S. Charney

Article

Monoamine Dysfunction and the Pathophysiology and Treatment of Depression

April 1, 1998

Dennis S. Charney

Ketamine Infusions and Written Exposure Therapy for Chronic PTSD

Building Resilience and Well-Being in Health Care Workers in the COVID-19 Era

Psychological Resilience in Frontline Health Care Workers During COVID-19

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression

Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the Cerebrospinal Fluid of Civilians With Posttraumatic Stress Disorder Before and After Treatment With Paroxetine

Reduced Posterior Hippocampal Volume in Posttraumatic Stress Disorder

Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Double-Blind, Randomized, Controlled Trial

Overview of Psychiatric Disorders and the Role of Newer Antidepressants

Norepinephrine Dysfunction in Depression

Models of Antidepressant Action

Monoamine Dysfunction and the Pathophysiology and Treatment of Depression

ELSEWHERE:

FOLLOW US:

Dennis S. Charney, MD

Ketamine Infusions and Written Exposure Therapy for Chronic PTSD

Building Resilience and Well-Being in Health Care Workers in the COVID-19 Era

Psychological Resilience in Frontline Health Care Workers During COVID-19

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression

Corticotropin-Releasing Factor, Interleukin-6, Brain-Derived Neurotrophic Factor, Insulin-Like Growth Factor-1, and Substance P in the Cerebrospinal Fluid of Civilians With Posttraumatic Stress Disorder Before and After Treatment With Paroxetine

Reduced Posterior Hippocampal Volume in Posttraumatic Stress Disorder

Pindolol Augmentation in Depressed Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Double-Blind, Randomized, Controlled Trial

Overview of Psychiatric Disorders and the Role of Newer Antidepressants

Norepinephrine Dysfunction in Depression

Models of Antidepressant Action

Monoamine Dysfunction and the Pathophysiology and Treatment of Depression

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles